Drug utilisation study of upadacitinib (Rinvoq™) in Europe to evaluate the effectiveness of additional risk minimisation measures

First published 12/02/2021

Last updated 02/04/2024

EU PAS number:

EUPAS39211

Study

Ongoing

Download as PDF

Documents

Study protocol

Initial protocol

p20199-protocol abstract-pmos_Redacted

English (183.53 KB - PDF)View document

Updated protocol

P20-199_Protocol v2.0_Abstract_Redacted

First published: 22/02/2024

English (155.12 KB - PDF)View document

Study results

Study report

Other information